CRTD researchers bring innovation from bench to bedside

idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo

06.05.2019 14:36

CRTD researchers bring innovation from bench to bedside

Kim-Astrid Magister Pressestelle
Technische Universität Dresden

    Novel process for the production of suppressive T cells
    The Center for Regenerative Therapies (CRTD) at the TU Dresden and the University Hospital Carl Gustav Carus have successfully developed a novel process for the automated proliferation of immunosuppressive cells for therapeutic purposes. This will initially benefit leukaemia patients after stem cell transplantation with severe inflammatory complications.

    A central task of the suppressive T cells found in the blood is the regulation of the immune defence, hence the name "Treg" cells. Through this influence, they can prevent the body's immune response from becoming too violent in healthy people. This happens, for example, in autoimmune diseases and chronic inflammatory diseases. The immune system not only attacks pathogens and infected cells, but also healthy tissue cells of the body. According to research results, regulatory T cells can counteract the development or progression of autoimmune diseases and weaken chronic inflammatory diseases. In order to be used as a therapy, however, they must be administered in very high doses by infusion. Since the proportion of cells in the blood is very low, they have to be isolated and subsequently multiplied for therapeutic application.

    In a planned clinical study at the Carl Gustav Carus University Hospital, the regulatory T cells will initially be used for the treatment of leukaemia patients. This is specifically for patients suffering from severe chronic graft-versus-host disease (cGvHD). A life-threatening complication affecting 50% of leukaemia patients after stem cell transplantation. Certain cell types of the transplant attack the tissue of the patient and lead to organ damage similar to an autoimmune disease. The aim of the study is to treat these patients with regulatory T-cells from the blood of their healthy stem cell donors at an early stage in order to attenuate or stop tissue destruction.

    The production and multiplication of regulatory T cells was developed into a fully automated process in the Good Manufacturing Practice (GMP) Facility of the CRTD, a technology platform for the production of novel drugs. In just two weeks, the CliniMACS Prodigy® system from partner Miltenyi Biotec will perform several fully automated feeding steps and sampling to produce a finished infusion solution. "The infusion bag containing the finished cell product is sterilely separated and sealed and can be brought directly to the patient's bed. This completely closed, standardised manufacturing process minimises the risk of contamination as well as the risk of potential quality deviations compared to the previous manual cell culture," explains project manager Dr. Anke Fuchs.

    Prof. Dr. med. Martin Bornhäuser, Director of the Medical Clinic and Polyclinic I of the University Hospital Carl Gustav Carus, emphasizes the advantages of the method: "The individualized application by using the donor's own cells is a look into the future of therapy development. The fact that we can conduct the study together with the CRTD facility at GMP level is a real exceptional feature."

    The clinical implementation of the project has been running since 2012 in an exchange between the GMP Facility of the CRTD and the Medical Clinic and Polyclinic I of the University Hospital Carl Gustav Carus. "This fruitful cooperation is a successful example of the close integration of research and clinical therapy in Dresden. With the publication of our automated process, we are laying the foundation for the standardized production of Treg preparations for different patient groups," says Dr. Anke Fuchs.

    Wissenschaftliche Ansprechpartner:

    Cornelia Probst
    Center for Regenerative Therapies Dresden (CRTD)
    Tel.: 0351 458-82065

    Friederike Braun
    Center for Regenerative Therapies Dresden (CRTD)
    Tel.: 0351 458-82064


    Merkmale dieser Pressemitteilung:
    Journalisten, Wissenschaftler
    Biologie, Medizin
    Forschungsergebnisse, Forschungsprojekte

    The Good Manufacturing Practice (GMP) Facility of the CRTD

    Zum Download


    Dr. Anke Fuchs

    Zum Download



    Die Suche / Erweiterte Suche im idw-Archiv

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.


    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).


    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.


    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).

    Cookies optimieren die Bereitstellung unserer Dienste. Durch das Weitersurfen auf erklären Sie sich mit der Verwendung von Cookies einverstanden. Datenschutzerklärung